[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 49 of about 49
1. Masue T, Taniguchi M, Takeuchi T, Sakai S: [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine]. Nihon Hinyokika Gakkai Zasshi; 2005 Sep;96(6):640-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine].
  • Cystoscopic examination revealed a broad-based tumor of 2.5 cm in diameter on the lateral side of the right ureteral orifice.
  • Under the clinical diagnosis of TCC G2 > G3, T3bNOM0, radical cystectomy with orthotopic bladder substitution was performed.
  • Pathological diagnosis was TCC G3 with sarcomatoid carcinoma, pT2pR0pL1 pVlpN0.
  • Adjuvant chemotherapy was not performed because of his transient poor conditions.
  • Lung metastasis was observed 6 months postoperatively.
  • Despite of M-VAC therapy and radiation therapy, additional metastases to brain and liver were observed.
  • To our knowledge, this is the first case of sarcomatoid carcinoma of the bladder with metastasis to small intestine, although 6 cases of transitional cell carcinoma of the bladder with metastasis to small intestine has been reported in Japan.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinosarcoma / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218407.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


2. Inoue T, Ohyama C, Horikawa Y, Togashi H, Matsuura S, Tsuchiya N, Satoh S, Sato K, Habuchi T, Saito S, Hoshi S, Arai Y, Kato T: [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma]. Hinyokika Kiyo; 2004 Apr;50(4):273-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
  • We report three cases with methotrexate-vinblastin-adriamycin-cisplatin (MVAC) resistant multiple liver metastases of urothelial carcinoma that responded to combination chemotherapy consisting of gemcitabine plus carboplatin (GC) with additional docetaxel (GCD) as salvage chemotherapy.
  • Case 1: A 55-year-old man underwent left nephroureterectomy for ureteral cancer (TCC, G3, pT3pN1M0).
  • Three courses of GC followed by three courses of GCD were given via intra-hepatic arterial infusion for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 2: A 46-year-old man underwent radical cystectomy for locally advanced bladder cancer (TCC G3 + adenocarcinoma. pT3pN0M0).
  • Two courses of GC followed by 2 courses of GCD systemic therapies were performed for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 3: A 66-year-old man received three courses of MVAC for multiple metastases of the bladder cancer (TCC, G3, > pT2), which resulted in disease progression.
  • Although the response duration was still short, GC and GCD may be promising salvage chemotherapeutic regimens for the patients with MVAC-resistant liver metastases of urothelial carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Taxoids / administration & dosage. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15188623.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


3. Nanaura H, Yamada Y, Fukatsu H: [A case of subcutaneous metastases from bladder cancer after radical cystouretherectomy]. Hinyokika Kiyo; 2002 Mar;48(3):179-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of subcutaneous metastases from bladder cancer after radical cystouretherectomy].
  • A case of transitional cell carcinoma (TCC) of the bladder metastasizing subcutaneously to the right lower abdomen and to the left back approximately 2 years after radical cystouretherectomy is reported.
  • A 65-year-old male underwent radical cystouretherectomy with the creation of ileal couduit after preoperative intraarterial chemotherapy and radiotherapy.
  • At the out patient clinic two years postoperatively, a subcutaneous tumor was palpated in the right lower abdomen and the left back.
  • The tumors were removed and histopathologically diagnosed as subcutaneous metastases of TCC.
  • The patient received three courses of postoperative systemic chemotherapy.
  • At 15 months after the last chemotherapy, the patient remains free of metastases and relapse.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Skin Neoplasms / secondary. Urethra / surgery. Urinary Bladder / surgery. Urinary Bladder Neoplasms / pathology. Urologic Surgical Procedures / adverse effects

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11993215.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


Advertisement
4. Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res; 2000 Dec;6(12):4866-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
  • To determine the prognostic value of angiogenesis factor expression for patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) chemotherapy and radical cystectomy, we evaluated the expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and interleukin 8 (IL-8) by in situ hybridization, and we determined microvessel density (MVD) by immunohistochemistry.
  • These factors were evaluated in 55 biopsy specimens prior to therapy and in the cystectomy specimens of 51 patients after completion of therapy.
  • Pathological stage, bFGF expression, and MVD in the cystectomy specimens after therapy were all independent prognostic factors for disease recurrence.
  • The results of this exploratory study indicate that the expression levels of VEGF and bFGF as indicated by in situ hybridization and MVD as indicated by immunohistochemistry identify patients with muscle-invasive TCC who are at high risk of developing metastasis after aggressive therapy with systemic M-VAC chemotherapy and radical cystectomy.
  • [MeSH-major] Angiogenesis Inducing Agents / biosynthesis. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / metabolism. Chemotherapy, Adjuvant. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Cystectomy. Disease-Free Survival. Doxorubicin / administration & dosage. Endothelial Growth Factors / biosynthesis. Female. Fibroblast Growth Factor 2 / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization. Interleukin-8 / biosynthesis. Lymphokines / biosynthesis. Male. Methotrexate / administration & dosage. Microcirculation. Middle Aged. Multivariate Analysis. Muscle Neoplasms / secondary. Neoplasm Metastasis. Prognosis. RNA, Messenger / metabolism. Recurrence. Time Factors. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11156246.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 67914; United States / NCI NIH HHS / CA / CA 71861
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Endothelial Growth Factors; 0 / Interleukin-8; 0 / Lymphokines; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


5. Kato S, Ito Y, Nishino Y, Ban Y, Deguchi T: [Urethral recurrence and distant metastases of bladder cancer 9 years after cystectomy and neobladder]. Hinyokika Kiyo; 2005 Mar;51(3):195-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence and distant metastases of bladder cancer 9 years after cystectomy and neobladder].
  • We report a 79-year-old female with urethral recurrence and distant metastases of urothelial bladder cancer.
  • Chemotherapy was not performed and the patient died 5 months later.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Nodes / pathology. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Diversion
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Urethral cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852676.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Vecchioli Scaldazza C, Giacomini G: [Repeated bladder metastases from renal cell carcinoma. Report of a case with particular attention to the use of immunomodulators]. Minerva Urol Nefrol; 2000 Dec;52(4):215-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repeated bladder metastases from renal cell carcinoma. Report of a case with particular attention to the use of immunomodulators].
  • The case of repeated metastases of the bladder from renal cell carcinoma in a 59 year old male patient is presented.
  • Two years after nephrectomy the ureteral stump and the bladder were interested by two different metastases.
  • Afterwards, other nine metastases developed into the bladder during the following 12 months.
  • Bladder metastases ranged between 2 and 4 mm.
  • No other metastasis was discovered by MRI and skeletal scintigraphy.
  • Thirteen months after the first bladder metastasis, intracavitary Bacillus Calmette-Guerin was used.
  • No report was found in the literature about BCG in the treatment of superficial bladder metastases from renal cell carcinoma.
  • However 15 months from beginning of BCG treatment no metastasis developed from the bladder that now is disease-free after a follow-up of 19 months.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11315333.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


7. Nabi G, Seth A, Dogra PN, Hemal AK, Gupta NP: Impact of primary tumour characteristics on the survival of patients with lymph node metastases in bladder cancer following radical cystectomy. Int Urol Nephrol; 2003;35(1):25-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of primary tumour characteristics on the survival of patients with lymph node metastases in bladder cancer following radical cystectomy.
  • BACKGROUND AND OBJECTIVE: Patients with carcinoma urinary bladder with metastasis to the lymph nodes have been believed to have a poor prognosis.
  • 38 of these were found to have metastasis in the regional lymph nodes (i.e. stage D).
  • Patients were studied for age, sex, morphology of tumour (papillary or nodular), grade of tumour, local extent of the disease (T1 T3A OR T3B), lymph nodal involvement, chemotherapy (whether received or not) and no. of TUR resection before radical cystectomy.
  • The benefits of adjuvant chemotherapy (methotrexate and cisplatin) could not be assessed as most of the patients received chemotherapy.
  • CONCLUSION: Patients with positive lymph nodes for metastases have fairly good survival with radical cystectomy especially those who have a lower T stage (organ confined), papillary morphology and N1 disease.
  • [MeSH-major] Cystectomy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Mar 15;73(6):1708-15 [8156499.001]
  • [Cites] J Urol. 2001 Jan;165(1):62-4; discussion 64 [11125364.001]
  • [Cites] J Urol. 1999 Feb;161(2):449-54 [9915424.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):179-89, xi-xii [10696257.001]
  • [Cites] J Urol. 1982 Jul;128(1):34-6 [7109065.001]
  • [Cites] J Urol. 1999 Jan;161(1):72-6 [10037372.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):3020-8 [8199999.001]
  • [Cites] J Urol. 1993 Apr;149(4):758-64; discussion 764-5 [8455238.001]
  • [Cites] Cancer. 2000 May 15;88(10):2326-32 [10820355.001]
  • [Cites] J Urol. 1981 Nov;126(5):591-3 [7299915.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1926-31 [8137219.001]
  • (PMID = 14620278.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Senovilla Pérez JL, Resel Estévez L, Moreno Sierra J, Fernández Pérez C, González Larriba JL, Blanco Jiménez E, Silmi Moyano A: [Neoadjuvant chemotherapy MVAC in the treatment of infiltrating bladder carcinoma]. Actas Urol Esp; 2000 Jul-Aug;24(7):536-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy MVAC in the treatment of infiltrating bladder carcinoma].
  • [Transliterated title] Quimioterapia neoadyuvante MVAC en el tratamiento del carcinoma vesical infiltrante.
  • INTRODUCTION: Aiming to preserve the bladder in patients with infiltrative carcinoma of the bladder and to offer patients improved quality of life with no detriment for survival, a therapeutical protocol was set up.
  • MATERIAL AND METHODS: Between August 1988 and January 1997 63 patients with stage T2 and T3a infiltrative carcinoma of the bladder, with no metastasis or node extension detectable with imaging techniques were treated in our unit.
  • 45 of these patients met all protocol criteria and were given 3 neoadjuvant chemotherapy courses with MVAC (methotrexate, vincristine, adriamycin, cisplatin).
  • Following chemotherapy, re-assessment was performed through lab tests, chest X-rays, abdomino-pelvic CT, bone scanning, cystoscopy, multiple randomized biopsies, tumoral bed scar resection and resection of relapsed urothelioma.
  • 20% received other therapies after rejecting both cystectomy or radiotherapy.
  • With regards to grading, 66.7% patients had lower grading at relapse if tumour was initially grade 2.
  • For those with initial tumour grade 3, only 20% had a lower grade.
  • CONCLUSION: 64.4% patients retained their bladder.
  • In 26.7% there was demonstrable metastatic disease.
  • No differences were seen in the distribution or survival time based on the different treatment given after chemotherapy (p = 0.22).
  • Patients with complete remission after chemotherapy have greater actuarial survival which is statistically significant (p = 0.04).
  • [MeSH-major] Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Survival Rate. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11011443.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


9. Simms MS, Mann G, Kockelbergh RC, Mellon JK: The management of lymph node metastasis from bladder cancer. Eur J Surg Oncol; 2005 May;31(4):348-56
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of lymph node metastasis from bladder cancer.
  • AIM: The presence of pelvic lymph node metastasis from bladder cancer has traditionally been associated with a very poor prognosis.
  • The aim of this paper is to review the literature with regard to the management of patients with nodal disease, particularly gross nodal metastasis and suggest a strategy for management of these patients.
  • METHODS: We performed a literature search in the PubMed database and the reference lists of relevant papers describing the management of locally advanced bladder cancer.
  • FINDINGS: There are no randomised studies relating specifically to the management of nodal metastasis in bladder cancer.
  • In patients with gross nodal disease detected pre-operatively or at the time of surgery, a multimodality approach consisting of surgery, chemotherapy and possibly radiotherapy seems appropriate.
  • The prognosis of such patients relates to the pathological stage of the primary tumour and the degree of lymph node involvement.
  • In addition a good response to neoadjuvant chemotherapy may identify patients who are likely to survive longer.
  • CONCLUSIONS: The prognosis for patients with gross nodal disease from bladder cancer is poor although cure may be possible in a small number of patients.
  • [MeSH-major] Lymphatic Metastasis. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymph Node Excision. Neoplasm Staging. Pelvis. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837038.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 60
  •  go-up   go-down


10. Sugawara Y, Kajihara M, Semba T, Ochi T, Fujii T, Mochizuki T: Healing focal "flare" phenomenon after radiotherapy in a bone metastasis from bladder cancer. Clin Nucl Med; 2005 Oct;30(10):672-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing focal "flare" phenomenon after radiotherapy in a bone metastasis from bladder cancer.
  • "Flare" phenomenon has been primarily reported as a transient increase in the number or intensity of lesions on bone scans in patients receiving hormonal or chemotherapy.
  • It has been well documented in patients with metastatic breast or prostate carcinoma, and recently reported in those with lung cancer.
  • We present a case of bone metastasis from bladder carcinoma, in which healing flare phenomenon was observed after radiotherapy.
  • [MeSH-major] Bone Neoplasms / etiology. Bone Neoplasms / secondary. Carcinoma / etiology. Carcinoma / secondary. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Aged. Humans. Male. Urinary Bladder Neoplasms / surgery


11. Chung P, Gospodarowicz M, Warde P, Qi-Long Y, Jewett M, Milosevic M, Bristow R, Moore M, Tannock I, McLean M: Long-term effects of conservation therapy for muscle invasive bladder carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of conservation therapy for muscle invasive bladder carcinoma.
  • : 4519 Background: A review of outcomes of radiotherapy-based bladder conserving therapy in patients with muscle invasive bladder cancer was performed to assess the long term outcomes.
  • METHODS: Of 131 patients with T2/T3aN0M0 (TNM 1992) transitional carcinoma of the bladder managed at Princess Margaret Hospital between 1986 and 1997, 108 were treated with radiotherapy alone, 20 with radiotherapy plus concurrent cisplatin and 3 with neoadjuvant chemotherapy plus radiotherapy.
  • Response was assessed with cystoscopy 6 weeks after completion of treatment.
  • Of 47 patients with recurrent disease, 31 relapsed in the bladder only, 3 in bladder and pelvis, 2 in bladder and metastases, and 10 with metastases only.
  • Salvage treatment for those with bladder only relapse (n=31) consisted of TUR/intravesical BCG in 52% (n=16) and cystectomy in 31% (n=11).
  • Prognostic factors for improved CSS and LRFR included absence of CIS, small primary tumor (≤2cm); patients who received chemotherapy had improved CSS.
  • CONCLUSIONS: RT based treatment of locally advanced bladder cancer results in bladder preservation in the majority of patients with T2-T3a N0M0 (TNM 1992) bladder cancer.
  • For select patients bladder conservation therapy with multimodality approach is an alternative to radical cystectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016029.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • RESULTS: The median age was 72(47-92), 2/3 of the patients were men; renal pelvis was the primary site in 21, upper ureter in 3; 13 (54%) were smokers; ten patients (42%)had bladder tumors either preceding the renal pelvis tumor or after; six (25%) of the patients had distant metastases; ten (42%) had nodal metastases;The median overall survival was 27 months.
  • The overall survival of patients with and without distant metastases was 5 months and 50 months respectively. (P=. 0004).
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • The overall survival of patients with distant metastases in bladder cancer varies from 9 months to 33 months depending on the performance status and visceral metastases.
  • CONCLUSIONS: The median survival of patients with metastatic renal pelvis and upper tract tumors is worse than bladder cancer.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yumura Y, Chiba K, Okada Y, Hirokawa M: [Brain metastasis of bladder carcinoma after total cystectomy: a case report]. Hinyokika Kiyo; 2000 Nov;46(11):807-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain metastasis of bladder carcinoma after total cystectomy: a case report].
  • A 74-year-old woman underwent total cystectomy with ureterostomy on March 1993 on a diagnosis of advanced bladder cancer.
  • The pathological diagnosis was transitional carcinoma grade 3, pT3a pN0 pV1, pL2.
  • Two courses of adjuvant chemotherapy with CDDP and MTX were added.
  • Brain MRI examination revealed a solid tumor, 4 x 4 x 3 cm in size, in the right frontal lobe of the cerebrum.
  • No other metastatic lesions were found.
  • She underwent surgical resection of the tumor and subsequent irradiation to right frontal lobe in the cerebrum.
  • Pathological examination confirmed its origin of bladder cancer.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Cystectomy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Treatment Outcome. Ureterostomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193302.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Nishimoto K, Oyama M, Ando T, Nakajima Y, Kiguchi H: [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report]. Hinyokika Kiyo; 2005 Nov;51(11):759-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report].
  • A 79-year-old man had undergone radical cystourethrectomy for bladder carcinoma in January, 1989.
  • Ten years later, follow-up computed tomography (CT) revealed swollen left inguinal lymph node in October 1998 and lymph node dissection was performed in January, 2000.
  • Left inguinal lymph node metastases appeared again in January, 2001.
  • Chest X-ray films showed multiple lung metastases in March, 2001.
  • Three couses of MVAC (methotrexate, vinblastine, doxorubicin cisplatinum) chemotherapy had been performed since September, 2001 but were in effective.
  • Papillary tumor was observed at external urethral meatus in September, 2002 and the biopsied specimens showed TCC, G1 > G2, pathologically.
  • It is suggested that the recurrent TCC tumor in the urethral remnants might metastasize into the inguinal lymph nodes.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Nodes / pathology. Urethra / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Humans. Inguinal Canal. Lymphatic Metastasis. Male. Time Factors

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • He underwent a tonsillectomy and a lymphadenectomy which both revealed melanoma metastases.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • Gastroscopy revealed bleeding from mucosal metastases of the esophagus and stomach.
  • A few weeks later the patient developed macroscopic hematuria.
  • A cystoscopy was performed and showed metastases to the mucosa of the bladder.
  • Nutrient vessels of these bladder metastases were embolized in order to control bleeding.
  • RESULTS: This case presents common and uncommon sites of metastatic melanoma to the mucosa with the typical clinical manifestations in a single patient.
  • [MeSH-major] Esophageal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary. Tonsillar Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


16. Boukriche Y, Bouccara D, Cyna-Gorse F, Dehais C, Felce-Dachez M, Masson C: [Sudden bilateral hearing loss disclosing meningeal carcinomatosis]. Rev Neurol (Paris); 2002 Jul;158(6-7):728-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four years before, a bladder carcinoma was resected and a chemotherapy was started.
  • Cerebrospinal fluid analysis showed malignant cells consistent with the initial bladder cancer.
  • Meningeal metastases from bladder carcinoma are extremely rare.
  • Systemic chemotherapy and its low meningeal diffusion may enhance the incidence of this complication.
  • [MeSH-major] Carcinoma / complications. Carcinoma / diagnosis. Hearing Loss, Bilateral / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cochlear Nerve / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Urinary Bladder Neoplasms / cerebrospinal fluid. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486903.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Hatano K, Kawashima A, Arai Y, Inoue H, Miyagawa Y, Takaha N, Nishimura K, Miyake O, Okuyama A: [Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report]. Hinyokika Kiyo; 2006 Oct;52(10):801-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report].
  • We report a case of bladder cancer with pelvic lymph node metastasis effectively treated by chemotherapy followed by radiotherapy.
  • After 31 months, computerized tomography (CT) revealed a bulky tumor (7.0 x 5.6 cm) along the left pelvic wall, indicating pelvic lymph node metastasis.
  • Five courses of chemotherapy consisting of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) was performed.
  • The size of the tumor was reduced to 1.5 x 1.0 cm.
  • Then, external beam radiotherapy (50 Gy) was added to the residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Lymph Nodes / pathology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Pelvis. Radiotherapy Dosage. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131872.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


18. Walvekar RR, Pantvaidya GH, Desai SB, Chaukar DA, D'Cruz AK: Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report. Auris Nasus Larynx; 2006 Dec;33(4):493-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report.
  • Hypopharyngeal cancers have a high propensity to distant metastasis.
  • However, metastasis to the urinary bladder as an initial presentation of distant spread has not been reported in literature.
  • We present a report of a patient with a treated and controlled pyriform sinus cancer who presented with complaints of dysuria, 8 months after completion of treatment.
  • Cystoscopy revealed a bladder mass and biopsy confirmed it to be a metastatic squamous cell carcinoma.
  • On further investigation, the patient was found to have disseminated disease for which chemotherapy was instituted.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hypopharyngeal Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Cystoscopy. Fatal Outcome. Humans. Male. Neck Dissection. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinus cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920307.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Rübben H, Otto T: [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy]. Urologe A; 2001 Nov;40(6):464-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy].
  • [Transliterated title] Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom. Aktuelle Aspekte in der Therapie.
  • The prognostic factors for infiltrating tumors established by the TNM system in 1997 include: Depth of infiltration, degree of differentiation, status of lymph nodes distant metastases.
  • Of the additional factors investigated, only tumor size and hydronephrosis appear to be of prognostic significance.
  • In cases of carcinoma of the urinary bladder without metastases (T2-4,N0,M0), radical cystectomy is the therapy of choice.
  • A preceding neoadjuvant systemic regimen of chemotherapy with three cycles of M-VAC (methotrexate, vinblastine, adriamycin, cisplatin) significantly improves the survival rate.
  • In patients with locally advanced urinary bladder carcinoma, however, adjuvant systemic chemotherapy with M-VAC after cystectomy and lymphadenectomy offers no advantages for survival.
  • Quality of life in patients with metastatic bladder cancer disease is improved by new cytotoxic drugs, i.e. gemcitabine or taxanes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / surgery. Neoadjuvant Therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Humans. Lymph Node Excision. Methotrexate / administration & dosage. Neoplasm Invasiveness. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760352.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


20. Quek ML, Flanigan RC: The role of lymph node density in bladder cancer prognostication. World J Urol; 2009 Feb;27(1):27-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of lymph node density in bladder cancer prognostication.
  • Pelvic lymph node metastases from bladder cancer occur in about 25% of patients undergoing radical cystectomy.
  • While the majority of patients with lymph node metastases will develop progressive disease, some patients do exhibit long-term survival with and without adjuvant chemotherapy.
  • The concept of lymph node density has been proposed as a means to stratify patient prognosis since it takes into account two important factors-the number of positive nodes (tumor burden) and the total number of nodes removed/examined (extent of dissection).
  • Due to the lack of agreement on the extent of lymphadenectomy, lymph node density facilitates standardization of lymph node staging, thus allowing for adjuvant therapies and clinical trials to be more uniformly applied.
  • We review the literature regarding the role of lymph node density in the prognostic stratification of node-positive bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis / pathology. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Jun;112(11):2401-8 [18383515.001]
  • [Cites] Cancer. 2008 Jun;112(11):2331-3 [18383514.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):66-71 [17208142.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Jun;7(6):777-9 [17555386.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1218-23; discussion 1223-4 [17698113.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Dec;4(6):1007-16 [15606329.001]
  • [Cites] J Urol. 2003 Mar;169(3):943-5 [12576818.001]
  • [Cites] J Urol. 2001 Jan;165(1):62-4; discussion 64 [11125364.001]
  • [Cites] J Urol. 1999 Feb;161(2):449-54 [9915424.001]
  • [Cites] J Urol. 2003 Jul;170(1):35-41 [12796639.001]
  • [Cites] J Urol. 1982 Jul;128(1):34-6 [7109065.001]
  • [Cites] J Urol. 2006 Jul;176(1):53-7; discussion 57 [16753366.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):89-95 [15613859.001]
  • [Cites] Urology. 2003 Jan;61(1):105-8 [12559278.001]
  • [Cites] BJU Int. 2003 Aug;92(3):187-8 [12887464.001]
  • [Cites] J Urol. 2001 Dec;166(6):2295-6 [11696756.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2358-65 [15800327.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2527-37 [11135212.001]
  • [Cites] J Urol. 2003 Mar;169(3):946-50 [12576819.001]
  • [Cites] J Urol. 2007 Apr;177(4):1273-5; discussion 1275-6 [17382708.001]
  • [Cites] J Urol. 1999 Jan;161(1):72-6 [10037372.001]
  • [Cites] J Urol. 2001 Jul;166(1):19-23 [11435814.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2368-74 [17041887.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):349-55 [16818190.001]
  • [Cites] J Urol. 2005 Jul;174(1):103-6 [15947587.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] ScientificWorldJournal. 2007 Mar 02;7:789-99 [17619762.001]
  • [Cites] J Urol. 1993 Apr;149(4):758-64; discussion 764-5 [8455238.001]
  • [Cites] J Urol. 2008 Mar;179(3):873-8; discussion 878 [18221953.001]
  • [Cites] J Urol. 2006 Aug;176(2):486-92; discussion 491-2 [16813874.001]
  • [Cites] J Urol. 2002 Mar;167(3):1295-8 [11832716.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2414-22; discussion 2422 [17085118.001]
  • [Cites] J Urol. 2004 Jul;172(1):85-9 [15201743.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):121-6 [18165646.001]
  • [Cites] J Urol. 2007 Mar;177(3):876-81; discussion 881-2 [17296365.001]
  • (PMID = 19020882.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 35
  •  go-up   go-down


21. Takayanagi N, Chiba H, Sagawa T, Hirayama Y, Tsuji Y, Sakamaki S: [A case of undifferentiated bladder carcinoma with axilla lymph node metastasis successfully treated with gemcitabine and cisplatin]. Gan To Kagaku Ryoho; 2003 Dec;30(13):2137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of undifferentiated bladder carcinoma with axilla lymph node metastasis successfully treated with gemcitabine and cisplatin].
  • A 68-year-old man diagnosed with undifferentiated bladder carcinoma underwent radical cystectomy in another hospital.
  • He was referred to our hospital, and diagnosed with axilla lymph node metastasis of bladder carcinoma based on test results.
  • Four cycles of GEM and CDDP chemotherapy were performed.
  • After the chemotherapy, the metastatic focus disappeared completely from the CT scan, and the case was considered to be CR.
  • It is suggested that this combination therapy may be useful for bladder carcinoma in advanced or metastatic stages.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Lymph Nodes / pathology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Axilla. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Drug Administration Schedule. Humans. Lymphatic Metastasis. Male

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14712779.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Nakatani T, Sugimura K, Naganuma T, Kamikawa S, Sugimoto T: Metastatic urinary bladder tumor from extragonadal germ cell tumor: a case report. Oncol Rep; 2002 Nov-Dec;9(6):1209-11
Genetic Alliance. consumer health - Extragonadal Germ Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic urinary bladder tumor from extragonadal germ cell tumor: a case report.
  • Investigations revealed a retroperitoneal tumor and left-sided cervical lymphadenopathy without abnormal findings in both testicles.
  • The diagnosis of extragonadal germ cell tumor was made based on a lymph node biopsy.
  • Following chemotherapy and retroperitoneal lymphoadenectomy, at outpatient follow-up, beta-HCG elevated again.
  • He complained of gross hematuria, cystoscopy showed a bladder tumor, and abdominal MRI scan showed a right ureteral tumor.
  • Total cystectomy and right nephroureterectomy were performed, which revealed that the bladder and ureteral tumors were metastatic germ cell tumors.
  • Six months later, the patient developed hepatic and mesenteric lymph node metastases that failed to respond to treatment, and died.
  • Germ cell tumors metastasizing to the urinary tract are extremely uncommon, and this is the first report of bladder metastases, other than through direct invasion, from an extratesticular germ cell tumor.
  • [MeSH-major] Germinoma / secondary. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Fatal Outcome. Humans. Liver Neoplasms / blood. Liver Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Radiography, Abdominal. Tomography, X-Ray Computed. Urinary Bladder Neoplasms / blood. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12375021.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


23. Kong PE, Snijdelaar DG, Crul BJ: [Parenteral administration of low dose ketamine for the treatment of neuropathic pain in cancer patients]. Ned Tijdschr Geneeskd; 2002 Dec 28;146(52):2556-8
Hazardous Substances Data Bank. KETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parenteral administration of low dose ketamine for the treatment of neuropathic pain in cancer patients].
  • [Transliterated title] Parenterale toediening van lage doseringen ketamine ter behandeling van neuropathische pijn bij patiënten met kanker.
  • In three patients, a 52-year-old woman with skeletal metastases from bladder carcinoma, a 54-year-old man with metastasised thyroid carcinoma and a 40-year-old man with a non-Hodgkin lymphoma, neuropathic pain developed that could not be alleviated adequately by patient-controlled opioid administration.
  • Pending invasive therapy, the three patients were given a continuous low dose of parenteral ketamine (2-5 micrograms/kg/min).
  • The pain in the first two patients responded so well to ketamine that they decided to waive the invasive pain treatment and to continue the ketamine infusion at home until death.
  • In the third patient, the addition of ketamine resulted in an adequate level of analgesia during the waiting period for invasive treatment with an intrathecal catheter.
  • [MeSH-major] Analgesics / therapeutic use. Ketamine / therapeutic use. Neoplasms / complications. Neuralgia / drug therapy. Palliative Care

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12532671.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics; 0 / Receptors, N-Methyl-D-Aspartate; 690G0D6V8H / Ketamine
  •  go-up   go-down


24. Saad F, Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol; 2010 Jun;37 Suppl 1:S38-44
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
  • Approximately 30% of patients with renal cell carcinoma (RCC) and 40% of patients with bladder cancer develop bone metastases that can disrupt normal bone homeostasis and place patients at risk for potentially life-limiting skeletal-related events (SREs).
  • In the absence of bone-directed therapies, patients with RCC may experience up to four SREs per year.
  • In patients with bone metastases from RCC or bladder cancer, zoledronic acid (ZOL) significantly reduced the risk of SREs compared with placebo.
  • In addition to its bone-protective effects, preclinical and early clinical evidence indicates that ZOL prevents tumor progression.
  • For example, retrospective subset analysis in patients with RCC indicated that ZOL extended time to disease progression and demonstrated a trend toward improved overall survival compared with placebo.
  • Additionally, a study in patients with bone metastases from bladder cancer demonstrated that ZOL improved 1-year overall survival compared with placebo.
  • Bone metastases place a heavy burden on patients with RCC or bladder cancer, and early, continuous treatment with ZOL may provide anticancer benefits in addition to important patient quality of life.
  • [MeSH-major] Bone Neoplasms / prevention & control. Carcinoma, Renal Cell / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Kidney Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Bone Density Conservation Agents / therapeutic use. Disease Progression. Humans. Survival Analysis


25. Shen CH, Shee JJ, Wu JY, Lin YW, Wu JD, Liu YW: Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol; 2010 Aug;160(8):2008-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.
  • BACKGROUND AND PURPOSE: Bladder cancer is a highly recurrent cancer after intravesical therapy, so new drugs are needed to treat this cancer.
  • Hence, we investigated the anti-cancer activity of combretastatin A-4 (CA-4), an anti-tubulin agent, in human bladder cancer cells and in a murine orthotopic bladder tumour model.
  • The effect of intravesical CA-4 therapy on the development of tumours was studied in the murine orthotopic bladder tumour model.
  • Cytotoxic IC(50) values of CA-4 in human bladder cancer cells were below 4 nM.
  • The analyses of apoptosis showed that CA-4 induced caspase-3 activation and decreased BubR1 and Bub3 in cancer cells.
  • Importantly, the in vivo study revealed that intravesical CA-4 therapy retarded the development of murine bladder tumours.
  • CONCLUSIONS AND IMPLICATIONS: These data demonstrate that CA-4 kills bladder cancer cells by inducing apoptosis and mitotic catastrophe.
  • It inhibited cell migration in vitro and tumour growth in vivo.
  • Hence, CA-4 intravesical therapy could provide another strategy for treating superficial bladder cancers.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Cell Proliferation / drug effects. Stilbenes / pharmacology. Tubulin Modulators / pharmacology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Dose-Response Relationship, Drug. Female. Humans. Inhibitory Concentration 50. Mice. Mice, Inbred C57BL. Microtubules / drug effects. Microtubules / metabolism. Neoplasm Invasiveness. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Time Factors. Tumor Burden / drug effects

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5287-97 [19738110.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3172-81 [19755861.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):1-14 [11156599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2735-41 [12171907.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Sep;43(3):277-86 [12270783.001]
  • [Cites] J Med Chem. 2006 Jun 1;49(11):3143-52 [16722633.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):844-52 [16740038.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3075-80 [16809732.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Apoptosis. 2003 Oct;8(5):413-50 [12975575.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):96-100 [14734457.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2825-37 [15077146.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4621-8 [15231674.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1401-11 [15466404.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):1056-66 [7037151.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 May;80(10):2926-30 [6574461.001]
  • [Cites] J Surg Oncol. 1988 Mar;37(3):177-84 [3352272.001]
  • [Cites] Experientia. 1989 Feb 15;45(2):209-11 [2920809.001]
  • [Cites] J Med Chem. 1995 May 12;38(10):1666-72 [7752190.001]
  • [Cites] Anticancer Drug Des. 1995 Jun;10(4):299-309 [7786396.001]
  • [Cites] Mol Carcinog. 1995 Jul;13(3):173-81 [7619220.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1829-34 [9157969.001]
  • [Cites] J Cell Sci. 1997 Sep;110 ( Pt 17):2013-25 [9378753.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):355-61 [10501907.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1527-33 [15746056.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2992-3006 [16224539.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34710-8 [10942766.001]
  • [Cites] BMC Cancer. 2006;6:280 [17156434.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3209-21 [17172425.001]
  • [Cites] Apoptosis. 2007 Jan;12(1):155-66 [17143747.001]
  • [Cites] World J Urol. 2007 Jun;25(3):285-95 [17530260.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Oct;323(1):365-73 [17646428.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):623-34 [17726580.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):419-30 [17991869.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1951-61 [18024794.001]
  • [Cites] Curr Opin Oncol. 2008 May;20(3):307-14 [18391631.001]
  • [Cites] Int Braz J Urol. 2008 Mar-Apr;34(2):220-6; discussion 226-9 [18462521.001]
  • [Cites] Expert Opin Pharmacother. 2008 Oct;9(15):2603-16 [18803448.001]
  • [Cites] Cancer Treat Rev. 2008 Dec;34(8):737-49 [18722718.001]
  • [Cites] Nat Rev Drug Discov. 2008 Dec;7(12):1013-30 [19043451.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • (PMID = 20649598.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; 0 / Tubulin Modulators; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; I5590ES2QZ / fosbretabulin
  • [Other-IDs] NLM/ PMC2958646
  •  go-up   go-down


26. Hadzi-Djokić J, Pejcić T, Aćimović M, Andrejević V, Radosavljević R: Penile metastasis from invasive bladder cancer. Acta Chir Iugosl; 2009;56(2):101-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile metastasis from invasive bladder cancer.
  • OBJECTIVE: To present the rare case of penile metastasis from bladder cancer.
  • PATIENT REPORT: A 68-year-old man with invasive bladder cancer disseminated in penile shaft and the pelvic lymph nodes is presented.
  • The patient underwent cystoprostatectomy, total penectomy and adjuvant chemotherapy.
  • CONCLUSION: Despite the fact that secondary penile tumors usually require palliative therapy, in selected cases surgical treatment of primary tumor and penectomy, followed with chemotherapy, can improve survival.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Penile Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Lymphatic Metastasis. Male. Pelvis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780339.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


27. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol; 2010 Aug;15(4):382-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
  • BACKGROUND: Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer.
  • The aim of this study was to evaluate the effect of zoledronic acid on SREs in patients with bone metastases from bladder cancer.
  • PATIENTS AND METHODS: Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months.
  • RESULTS: The patients (n = 40) were evenly distributed between the two treatment groups, and the baseline demographics of the two groups were similar.
  • Zoledronic acid also prolonged the median time to first SRE compared with the placebo (16 vs. 8 weeks, respectively).
  • CONCLUSIONS: Zoledronic acid therapy decreased the incidence of SREs and improved the 1-year survival rate of patients with bone metastases from bladder cancer, potentially through its anticancer activity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Density Conservation Agents / administration & dosage. Bone Neoplasms / drug therapy. Diphosphonates / administration & dosage. Imidazoles / administration & dosage. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Egypt. Female. Fractures, Bone / etiology. Fractures, Bone / prevention & control. Humans. Hypercalcemia / etiology. Hypercalcemia / prevention & control. Kaplan-Meier Estimate. Male. Middle Aged. Pain / etiology. Pain / prevention & control. Placebo Effect. Prospective Studies. Risk Assessment. Risk Factors. Spinal Cord Compression / etiology. Spinal Cord Compression / prevention & control. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jun 15;100(12):2613-21 [15197804.001]
  • [Cites] Cancer Treat Rev. 2008;34 Suppl 1:S19-24 [18486348.001]
  • [Cites] Support Cancer Ther. 2007 Jan 1;4(2):92-100 [18632473.001]
  • [Cites] Med Oncol. 2005;22(2):195-201 [15965284.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3150-7 [12915606.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):743-9 [8616767.001]
  • [Cites] J Urol. 2009 Apr;181(4):1587-93; discussion 1593 [19233433.001]
  • [Cites] Int J Cancer. 2009 Oct 1;125(7):1705-9 [19521984.001]
  • [Cites] Stat Methods Med Res. 2002 Apr;11(2):141-66 [12040694.001]
  • [Cites] Ann Acad Med Singapore. 1994 Mar;23(2):129-38 [8080219.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Med Oncol. 2007;24(2):227-30 [17848748.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Cancer Treat Rev. 2008 Aug;34(5):453-75 [18423992.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1735-44 [14534891.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] Med Oncol. 2008;25(3):346-9 [18204821.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):879-82 [15173273.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):986-9 [16533874.001]
  • [Cites] Oncologist. 2008 May;13(5):503-14 [18515735.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):31-8 [18458903.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):165-76 [11417967.001]
  • [Cites] Blood. 2000 Jul 15;96(2):384-92 [10887096.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Cancer. 1977 Feb;39(2 Suppl):973-80 [402205.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):183-92 [18061356.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6 Suppl 4):S17-23 [18068486.001]
  • (PMID = 20354750.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


28. Singh AV, Franke AA, Blackburn GL, Zhou JR: Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res; 2006 Feb 1;66(3):1851-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis.
  • A role of dietary bioactive components in bladder cancer prevention is biologically plausible because most substances or metabolites are excreted through the urinary tract and are consequently in direct contact with the mucosa of the bladder.
  • We first determined antigrowth activity of genistein against poorly differentiated 253J B-V human bladder cancer cells in vitro.
  • Genistein inhibited the cell growth in a time- and dose-dependent manner via G(2)-M arrest, down-regulation of nuclear factor kappaB (NF-kappaB), and induction of apoptosis.
  • We also evaluated both genistin, which is a natural form of genistein, and the isoflavone-rich soy phytochemical concentrate (SPC) on the growth and metastasis of 253J B-V tumors in an orthotopic tumor model.
  • Mice treated with genistin and SPC had reduced final tumor weights by 56% (P < 0.05) and 52% (P < 0.05), respectively, associated with induction of tumor cell apoptosis and inhibition of tumor angiogenesis in vivo.
  • In addition, SPC treatment, but not genistin treatment, significantly inhibited lung metastases by 95% (P < 0.01) associated with significant down-regulation of NF-kappaB expression in tumor tissues and reduction of circulating insulin-like growth factor-I levels, suggesting that SPC may contain other bioactive ingredients that have antimetastatic activity.
  • The results from our studies suggest that further clinical investigation should be warranted to apply soy phytochemicals, such as SPC, as a potent prevention regimen for bladder cancer progression.
  • This orthotopic human bladder tumor model also provides a clinically relevant experimental tool for assessing potential preventive activity of other dietary components against bladder tumor growth and metastasis.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1999 Nov;54(5):823-8 [10565741.001]
  • [Cites] Biochem Pharmacol. 2005 Jan 15;69(2):307-18 [15627483.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):143-53 [12242729.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Sep 25;777(1-2):45-59 [12270199.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1674-7 [12496060.001]
  • [Cites] J Nutr. 2003 Jul;133(7):2262-7 [12840190.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):800-6 [15170660.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):319-23 [15352046.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3240-5 [1192400.001]
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6):1093-100 [1659780.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Feb;6(1):1-30 [1556044.001]
  • [Cites] Ann Urol (Paris). 1992;26(5):281-93 [1485797.001]
  • [Cites] Clin Chim Acta. 1993 Dec 31;223(1-2):9-22 [8143372.001]
  • [Cites] J Nutr. 1994 Jun;124(6):825-32 [8207540.001]
  • [Cites] Nutr Cancer. 1994;21(2):113-31 [8058523.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jan;52(1):97-103 [7857879.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):733S-743S [7884559.001]
  • [Cites] J Urol. 1995 Oct;154(4):1532-8 [7658585.001]
  • [Cites] Nutr Cancer. 1995;24(1):1-12 [7491293.001]
  • [Cites] J Biol Chem. 1996 Feb 2;271(5):2746-53 [8576250.001]
  • [Cites] Hinyokika Kiyo. 1995 Dec;41(12):969-77 [8578986.001]
  • [Cites] Nutr Cancer. 1996;26(3):289-302 [8910911.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2916-21 [9230201.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5231-8 [9823337.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):775-82 [9833772.001]
  • [Cites] J Nutr. 1999 Sep;129(9):1628-35 [10460196.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):230-6 [10656454.001]
  • (PMID = 16452247.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; United States / NCI NIH HHS / CA / R01 CA092546; None / None / / P30 DK040561-11; United States / NCI NIH HHS / CA / R03 CA112640-01; United States / NIDDK NIH HHS / DK / P30 DK040561-11; United States / NCI NIH HHS / CA / CA112640-01; United States / NCI NIH HHS / CA / R01 CA 92546; United States / NCI NIH HHS / CA / R03 CA112640; United States / NCI NIH HHS / CA / R01 CA092546-01A2; United States / NCI NIH HHS / CA / CA092546-01A2; United States / NCI NIH HHS / CA / R03 CA 112640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Isoflavones; 0 / NF-kappa B; 103107-01-3 / Fibroblast Growth Factor 2; 67763-96-6 / Insulin-Like Growth Factor I; DH2M523P0H / Genistein
  • [Other-IDs] NLM/ NIHMS109672; NLM/ PMC2683370
  •  go-up   go-down


29. Ide H, Nakajima Y, Horinaga M, Shinojima T, Ozu C, Hatakeyama N, Kiguchi H: [Bladder carcinoma metastases presenting as intraperitoneal dissemination without local recurrence: a case report]. Nihon Hinyokika Gakkai Zasshi; 2004 Nov;95(7):813-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder carcinoma metastases presenting as intraperitoneal dissemination without local recurrence: a case report].
  • Cystoscopy showed broad-based papillary tumors on the left bladder wall.
  • TUR-BT was performed and pathological diagnosis was grade 3 transitional cell carcinoma of pT1a.
  • Although no intravesical tumor recurrence had been observed, a solid palpable mass was noted in the lower abdomen nine months after TUR-BT, and computed tomography suggested a large ovarian tumor.
  • Subsequently performed was the operation at Gynecology, which revealed a large tumor involving the whole major omentum.
  • Frozen sections of the tumor were diagnosed as transitional cell carcinoma metastases of the bladder cancer, and the final pathological report was the same.
  • Although receiving 4 courses of M-VAC systemic chemotherapy after the operation, she died 14 months later.
  • Autopsy disclosed intraperitoneal cancer dissemination and metastases without any intravesical nor left perivesical tumor recurrence, and it was suggested that the bladder tumor metastases occurred not by direct invasion but by either lymphatic or vascular mechanism in this case.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Neoplastic Cells, Circulating / pathology. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624492.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Nakayama T, Yoshida S, Fujii Y, Koga F, Saito K, Masuda H, Kobayashi T, Kawakami S, Kihara K: [Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary]. Nihon Hinyokika Gakkai Zasshi; 2008 Nov;99(7):737-41
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary].
  • We report a case in which treatment response to lymph node metastatic bladder cancer was monitored by DW-MRI.
  • A 67-year-old man had paraaortic lymph node metastasis from bladder cancer; the paraaortic lymph node showed high signal intensity on DW-MRI.
  • After four course treatment of gemcitabine and cisplatin, the lesion showed reduction of signal intensity on DW-MRI and increase of the apparent diffusion coefficient value.
  • These signal changes were consistent with the change of morphological images (CT, MRI (T1-W, T2-W)), 18F-FDG PET and tumor markers.
  • This case suggests that DW-MRI is useful in monitoring treatment response of metastatic bladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diffusion Magnetic Resonance Imaging. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068691.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Nabi G, Gupta NP, Gandhi D: Skeletal muscle metastasis from transitional cell carcinoma of the urinary bladder: clinicoradiological features. Clin Radiol; 2003 Nov;58(11):883-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal muscle metastasis from transitional cell carcinoma of the urinary bladder: clinicoradiological features.
  • AIM: To define the clinicoradiological characteristics of skeletal muscle metastasis from transitional cell carcinoma of the urinary bladder.
  • MATERIALS AND METHODS: A retrospective review of all patients with skeletal muscle metastasis was undertaken between January 1999 to December 2001.
  • Patients suspected of having a metastasis on radiological examinations, and subsequently proven to have metastatic disease on histological examination were included in study.
  • The clinical presentation and radiological features of five patients with skeletal muscle metastasis from bladder tumours were reviewed from hospital records.
  • RESULTS: Twenty-four patients had skeletal muscle metastasis from various primaries.
  • Of these five patients had previous or concurrent primary tumours in the bladder.
  • Four patients had radical cystectomy with urinary diversion (two ileal conduit and two orthotopic sigmoid neobladder).
  • One patient presented with bladder tumour and concomitant muscular metastasis.
  • All patients underwent helical computed tomography (CT) before confirmation of diagnosis by fine-needle aspiration (FNA) or biopsy.
  • The typical appearance of low-density enhancing lesions on CT was mistaken for abscess in two patients and failure to respond to conservative treatment led to suspicion of metastasis.
  • Diagnosis was proven histologically in all patients (FNA in three and biopsy in two).
  • All patients had palliative chemotherapy (Mitomycin, Vincristine, Adriamycin and Cyclophosphamide).
  • CONCLUSION: Muscular metastasis from urothelial tumours typically presents with persistent localized pain with or without swelling.
  • The characteristic low-density, ring-enhancing lesions on CT in a patient with previous or concomitant urothelial tumours should raise the suspicion of metastasis until proven otherwise.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Muscle Neoplasms / secondary. Muscle, Skeletal. Urinary Bladder Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Biopsy / methods. Combined Modality Therapy / methods. Humans. Male. Middle Aged. Palliative Care / methods. Retrospective Studies. Time Factors. Tomography, Spiral Computed / methods

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14581013.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Torres Lobatón A, Cruz Ortiz H, Rojo Herrera G, Avila Medrano L: [Sarcomas of the vulva. Report of 2 cases]. Ginecol Obstet Mex; 2000 Oct;68:429-34
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sarcomas de la vulva. Informe de dos casos.
  • Along a 22 years follow-up the disease has had four local recurrences of more than 5 cm each one: two after surgery and two after surgery plus chemotherapy and surgery plus radiotherapy respectively.
  • She is alive disease evidence after two years from the last combined treatment.
  • The second one, was a 26 years-old patient with a malignant schwannoma of 12 cm in diameter treated with combined radical surgery, radiotherapy, and chemotherapy.
  • Treatment of vulvar sarcomas is radical local excision followed mainly by radiotherapy with infiltrating margins.
  • The value of postoperative adjuvant chemotherapy is uncertain.
  • According to the natural history and behavior of vulvar sarcomas, we conclude that the elective treatment of these tumors should be carry out in institutions of high level.
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / secondary. Adolescent. Adult. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bartholin's Glands. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cystectomy. Cysts / diagnosis. Dacarbazine / administration & dosage. Dacarbazine / therapeutic use. Diagnosis, Differential. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / secondary. Radioisotope Teletherapy. Retrospective Studies. Treatment Outcome. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11138405.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 12
  •  go-up   go-down


33. Morgan K, Srinivas S, Freiha F: Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. Urology; 2004 Oct;64(4):808-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
  • Metastasis from bladder cancer to the testis is extremely rare, occurs with advanced and metastatic disease, and is usually a finding at autopsy.
  • We report a rare, and probably the first, case of solitary and synchronous metastatic transitional cell carcinoma of the bladder to the testis, discovered on the preoperative workup.
  • An incidentally discovered testicular mass in a man with high-grade, invasive bladder cancer should be considered a metastatic lesion until proven otherwise.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Deoxycytidine / analogs & derivatives. Testicular Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Cystitis / complications. Cystitis / diagnosis. Hematuria / etiology. Humans. Incidental Findings. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary. Orchiectomy. Positron-Emission Tomography. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / secondary. Radiation Injuries / complications. Radiation Injuries / diagnosis. Transurethral Resection of Prostate. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15491734.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Eccles SA: Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2. IDrugs; 2010 Nov;13(11):768-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2.
  • The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment.
  • This conference report highlights selected presentations on translation targets from a clinical perspective, antibody inhibitors of TGFβ for metastasis suppression, metastasis in bladder and lung cancer, c-ErbB2/HER2 expression in ductal carcinomas in situ and breast cancer, targeting Hsp90 chaperones in solid cancers, peritoneal carcinomas, and the discovery and exploitation of RANK ligands in bone metastasis.
  • Investigational drugs discussed include the humanized antibody against TGFβ fresolimumab (GC-1008; Genzyme), the anti-VEGFR1 antibody icrucumab (IMC-18F1; ImClone Systems) and the novel Hsp90 inhibitor NVP-AUY-922 (AUY-922, VER-52296; Novartis).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Design. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Drug Delivery Systems. Drugs, Investigational / pharmacology. Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046523.001).
  • [ISSN] 2040-3410
  • [Journal-full-title] IDrugs : the investigational drugs journal
  • [ISO-abbreviation] IDrugs
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  •  go-up   go-down


35. Gómez-Román JJ, Cobo ML, Val-Bernal JF: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int; 2008 Apr;58(4):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm.
  • Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration.
  • Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm.
  • The morphological differential diagnosis was complex because the EMA-positive immunophenotype, CD45 and CD3 negativity and the clinical manifestation simulated a transitional cell carcinoma.
  • It is important to be aware of its existence because a poorly differentiated bladder carcinoma cannot be ruled out if CD30 and ALK immunostaining are not performed.
  • Although bladder involvement by recurrent lymphoma is a sign of widely disseminated disease and it is associated with a very poor prognosis, it seems that chemotherapeutic regimens in this kind of ALK-positive lymphoma could be effective, given that the present patient had an impressive response to chemotherapy treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / metabolism. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Etoposide / administration & dosage. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Mucin-1 / metabolism. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324919.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Mucin-1; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


36. Sun HZ, Wu SF, Tu ZH: Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res; 2001 Jun;11(2):107-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity.
  • A major problem which is poorly understood in the management of bladder cancer is low sensitivity to chemotherapy and high recurrence after transurethral resection.
  • Insulin-like growth factor 1 receptor (IGF-1R) signaling plays a very important role in progression, invasion and metastasis of bladder cancer cells.
  • In this study, we investigated whether IGF-1R was involved in the growth stimulating activity and drug resistance of bladder cancer cells.
  • These results suggested that blockage of IGF-IR signaling might potentially contribute to the treatment of bladder cancer cells which are insensitive to chemotherapy.
  • [MeSH-major] Antibiotics, Antineoplastic / agonists. Carcinoma, Transitional Cell / metabolism. Cytotoxins / agonists. Drug Resistance, Neoplasm / physiology. Mitomycin / agonists. Receptor, IGF Type 1 / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Autocrine Communication / drug effects. Autocrine Communication / genetics. Cell Division / drug effects. Cell Division / genetics. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / physiology. Gene Targeting. Humans. Insulin-Like Growth Factor I / genetics. Insulin-Like Growth Factor I / pharmacology. Insulin-Like Growth Factor II / genetics. Microscopy, Electron. Oligodeoxyribonucleotides, Antisense / pharmacology. Protein Synthesis Inhibitors / pharmacology. RNA, Messenger / metabolism. Signal Transduction / drug effects. Signal Transduction / genetics. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Tumor Cells, Cultured / ultrastructure

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11453542.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cytotoxins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 50SG953SK6 / Mitomycin; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


37. Zennami K, Yamada Y, Nakamura K, Aoki S, Taki T, Honda N: Solitary brain metastasis from pT1, G3 bladder cancer. Int J Urol; 2008 Jan;15(1):96-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary brain metastasis from pT1, G3 bladder cancer.
  • Brain metastasis from bladder cancer occurs rarely.
  • Particularly, solitary brain metastasis is very rare in patients who have never received systemic chemotherapy.
  • We encountered a patient who underwent transurethral resection of bladder tumor and bacillus Calmette-Guérin bladder instillation for pT1, G3 bladder cancer accompanied by carcinoma in situ, and subsequently revealed solitary brain metastasis after 34 months while neither cystoscopy nor urine cytology revealed abnormalities during this period.
  • To our knowledge, our experience of solitary brain metastasis from pT1 bladder cancer is the second case in the world.
  • [MeSH-major] Brain Neoplasms / secondary. Parietal Lobe. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184184.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


38. Segawa N, Azuma H, Takahara K, Hamada S, Kotake Y, Tsuji M, Katsuokai Y: [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report]. Hinyokika Kiyo; 2008 Jan;54(1):13-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis after retroperitoneoscopy-assisted nephroureterectomy and cystectomy for bladder cancer invading the ureter: a case report].
  • We report a case of port-site metastasis of bladder cancer after left retroperitoneoscopy-assisted nephroureterectomy and cystectomy.
  • The diagnosis was invasive bladder cancer with bone metastasis.
  • He received two courses of chemotherapy (methotrexate, vinblastine, adriamycin, cisplatin), and this resulted in resolution of the bone metastases.
  • Two months later, abdominal and pelvic computed tomography showed a bladder tumor invading the left lower ureter with hydronephrosis.
  • The patient was unable to undergo systemic chemotherapy because of renal dysfunction.
  • Four months later, a lateral abdominal wall tumor was found at a port-site, and needle biopsy confirmed this to be metastatic urothelial carcinoma.
  • Clinicians need to be aware of port-site metastasis, particularly in patients with UC, and take steps to prevent it during laparoscopic procedures.
  • [MeSH-major] Abdominal Neoplasms / secondary. Carcinoma / surgery. Cystectomy. Endoscopy. Neoplasm Invasiveness. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260354.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Farhat MH, Moumneh G, Jalloul R, El Hout Y: Secondary adenocarcinoma of the urinary bladder from a primary gastric cancer. J Med Liban; 2007 Jul-Sep;55(3):162-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary adenocarcinoma of the urinary bladder from a primary gastric cancer.
  • Primary bladder tumor is a frequent urological malignancy, whereas the incidence of secondary bladder tumor from a distant organ is quite rare.
  • Secondary bladder neoplasms represent no more than 3% of all malignant bladder tumors in surgical specimens, of which distant metastases from stomach account for about 4%.
  • The signs of bladder neoplasm in a patient with malignancy elsewhere should alarm the clinician for a possible metastatic origin.
  • We present a patient with primary adenocarcinoma of the stomach, who underwent total gastrectomy and received adjuvant chemotherapy, and was diagnosed with metastasis to the urinary bladder 15 months later.
  • We review the epidemiology of secondary adenocarcinoma of the bladder, mechanisms of metastasis, associated common primaries with focus on gastric malignancies, radiological findings, and role of immunohistochemical staining.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Med Liban. 2008 Jan-Mar;56(1):48 [19534093.001]
  • (PMID = 17966739.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Lebanon
  • [Number-of-references] 16
  •  go-up   go-down


40. Lekas A, Papathomas TG, Papatsoris AG, Deliveliotis C, Lazaris AC: Novel therapeutics in metastatic bladder cancer. Expert Opin Investig Drugs; 2008 Dec;17(12):1889-99
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutics in metastatic bladder cancer.
  • BACKGROUND: Albeit transitional cell carcinoma of the urinary bladder is a chemosensitive neoplasm, metastatic disease is related with poor prognosis and short-term survival data.
  • OBJECTIVE: Cisplatin-based combination chemotherapy is recognised as the golden standard therapy for patients with inoperable locally advanced or metastatic bladder cancer.
  • However, owing to treatment-related toxicities and short-response durations, novel treatment options or agents, with both enhanced efficacy and tolerability, have been sought.
  • METHODS: Reviewing the current status and addressing the future of novel anticancer therapeutics in metastatic urinary bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Platinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012504.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  • [Number-of-references] 120
  •  go-up   go-down


41. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report.
  • Metastatic carcinoma in an abdominal wall incision from internal malignant neoplasm is an uncommon and often a preterminal event.
  • Most commonly metastatic skin incisional cancers have been reported with cancers of colon, kidney, and bladder.
  • Incisional metastasis from postoperative case of carcinoma cervix is very rare.
  • We report a postoperative case of squamous cell carcinoma cervix FIGO stage IIA in a patient who after 3.5 years of completion of radical treatment (postoperative external and intravaginal radiation therapy) developed incisional skin metastasis followed by extensive subcutaneous metastasis in the vulval region.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.
  • The outcome of patients with incisional skin metastasis is usually poor as they are often associated with locoregional recurrence.
  • The intent of treatment remains palliation either by radiation/chemotherapy/surgery alone or in combinations.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Gynecologic Surgical Procedures. Humans. Radiotherapy


42. Kaneko G, Kikuchi E, Hasegawa M, Miyajima A, Nakagawa K, Kameyama K, Oya M: Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature. Int J Clin Oncol; 2010 Dec;15(6):626-30
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature.
  • A 74-year-old female was referred to our hospital for non-muscle invasive bladder tumors initially treated at another hospital.
  • Preoperatively, computed tomography and magnetic resonance imaging demonstrated non-muscle invasive bladder tumors and a vaginal tumor.
  • A second transurethral resection of the bladder tumors, transvaginal tumor resection, and systemic chemotherapy were performed.
  • The pathogenesis of the vaginal UC was considered to be the primary UC or metastasis from the bladder UC.
  • [MeSH-major] Carcinoma, Papillary / secondary. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nippon Med Sch. 2008 Oct;75(5):312-5 [19023174.001]
  • [Cites] Int J Gynecol Cancer. 1999 Jul;9(4):302-306 [11240783.001]
  • [Cites] Br J Urol. 1991 Jan;67(1):102-3 [1993264.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1138-45 [7573672.001]
  • [Cites] J Urol. 1984 Nov;132(5):904-6 [6492279.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):233-4 [10410896.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):299-301 [9496835.001]
  • [Cites] Urology. 1985 May;25(5):524-6 [3992780.001]
  • [Cites] Int J Gynecol Pathol. 1987;6(1):29-39 [3570630.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):669-70 [15863178.001]
  • [Cites] Urology. 2009 Jan;73(1):210.e3-5 [18372021.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2001 May;92(4):538-41 [11449707.001]
  • [Cites] J Oral Surg. 1981 Dec;39(12):972-4 [6948101.001]
  • [Cites] J Urol. 1985 Jul;134(1):58-61 [4009824.001]
  • [Cites] Hinyokika Kiyo. 2004 Apr;50(4):283-6 [15188625.001]
  • [Cites] Urol Int. 2001;67(1):117-8 [11464136.001]
  • [Cites] Virchows Arch. 2001 Feb;438(2):181-91 [11253121.001]
  • [Cites] Urology. 1989 Jun;33(6):477-80 [2728151.001]
  • [Cites] Cancer. 1997 May 15;79(10):1933-43 [9149020.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2447-56 [8402462.001]
  • [Cites] Histopathology. 1994 Jun;24(6):581-3 [8063289.001]
  • [Cites] Scand J Urol Nephrol. 1994 Jun;28(2):201-2 [7939475.001]
  • [Cites] Pathol Res Pract. 1990 Jun;186(3):358-64 [2377571.001]
  • [Cites] J Urol. 1972 Aug;108(2):277-8 [5047417.001]
  • [Cites] Scand J Urol Nephrol. 1998 Feb;32(1):73-6 [9561583.001]
  • [Cites] Int J Urol. 2006 Nov;13(11):1454-5 [17083404.001]
  • [Cites] Br J Urol. 1991 Jun;67(6):660-1 [2070221.001]
  • [Cites] Scand J Urol Nephrol. 1997 Feb;31(1):107-8 [9060095.001]
  • (PMID = 20544250.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Wermeński K, Kopyś-Wiszniewska I: [Value of diagnostic imaging for assessment of unsuccessful treatment of children with neoplastic diseases. Introductory comments based on personal examinations]. Med Wieku Rozwoj; 2000 Apr-Jun;4(2 Suppl 2):103-13
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of diagnostic imaging for assessment of unsuccessful treatment of children with neoplastic diseases. Introductory comments based on personal examinations].
  • [Transliterated title] Wartość badań obrazowych dla diagnostyki niepowodzeń leczenia dzieci z choroba nowotworowa. Doniesienie wstepne na podstawie własnych badań.
  • This is a precise and fine instrument for monitoring effects of treatment in childhood malignant tumours.
  • Authors demonstrate examples of cases in which diagnostic imaging was the only method which revealed a relapse in situ, progression during chemotherapy or clinically unsuspected dissemination of tumours after many years.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Bone Neoplasms / diagnosis. Diagnostic Imaging / methods. Fibromatosis, Aggressive / diagnosis. Neoplasm Recurrence, Local / diagnosis. Osteosarcoma / diagnosis. Rhabdomyosarcoma, Embryonal / diagnosis
  • [MeSH-minor] Adolescent. Carcinoma in Situ / diagnosis. Child, Preschool. Cicatrix / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178334.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


44. Bien E, Stachowicz-Stencel T, Balcerska A, Godzinski J, Kazanowska B, Perek-Polnik M, Madziara W, Rybczynska A, Kurylak A, Zalewska-Szewczyk B, Peregud-Pogorzelski J: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours Study. Eur J Cancer Care (Engl); 2009 Jul;18(4):411-20
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report of the Polish Paediatric Rare Tumours StudyAngiosarcoma is a rare, highly malignant vascular neoplasm with little data available on its clinical course and management in children.
  • Ten children with angiosarcoma (M/F: 6/4; aged 2, 3-16 years) registered in Polish Paediatric Rare Tumours and Soft Tissue Sarcomas Studies between 1992 and 2006.
  • Primary tumour exceeded 5 cm in seven patients and affected mainly deep tissues (heart-2, head/neck, bladder, brain, liver and upper limb - one patient each).
  • Four patients had regional and two metastatic diseases (lungs and bones).
  • All patients received supplementing chemotherapy with no response in four.
  • Three of five secondary tumour resections proved complete.
  • Seven patients experienced relapses (mainly metastatic) and two continuous progression.
  • Relapsed patients received chemotherapy +/- radiotherapy and surgery (three).
  • Nine patients died of disease (overall survival 6-66 months), and one child after mutilating secondary resection is alive.
  • The response to chemotherapy is poor and the large number of metastatic recurrences suggests a need for systemic therapy modifications.
  • [MeSH-major] Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Humans. Male. Poland / epidemiology. Prognosis. Radiotherapy. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490008.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • For the TCCs, 58.6% were superficial while 41.4% were muscle invasive, and 13.3% had nodal metastasis with distant metastasis in 8%.
  • Of the total, 5.3% were papillary urothelial tumours of low malignant potential, 33.3% pTa, 20% pT1, 10.7% pT2, 12.0% pT3 and 18.7% pT4.
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • Mean survival of patients with muscle invasive cancer was 33+/-5 months.
  • By the end of the study, 18.1% of patients had died of their cancer.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Malaysia. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


46. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, Dinney CP: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res; 2000 Jul;6(7):2635-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
  • Vascular endothelial cell growth factor (VEGF) regulates angiogenesis and metastasis of bladder cancer (transitional cell carcinoma, TCC) through binding to VEGF receptor-2 (VEGFR-2).
  • In this study, we evaluated whether the anti-VEGFR monoclonal antibody (Mab) DC101 in combination with paclitaxel inhibited tumorigenesis, angiogenesis, and metastasis of human TCC growing within the bladder of athymic nude mice.
  • In vivo therapy with Mab DC101 and paclitaxel induced significant regression of bladder tumors compared with either agent alone.
  • Median bladder weights were reduced from 601 mg in untreated controls, 422 mg in mice treated with paclitaxel alone (P < 0.005), 361 mg in mice treated with DC101 alone (P < 0.005), and 113 mg in mice that received combination therapy (P < 0.0005).
  • Only one of nine mice developed spontaneous lymph node metastasis after combined treatment, compared with seven of seven untreated controls (P < 0.0005), six of eight after DC101 (P < 0.01), and five of eight mice after paclitaxel (P < 0.05).
  • Combined treatment with both paclitaxel and DC101 inhibited tumor-induced neovascularity compared with all other groups (P < 0.005), without altering the expression of VEGF or flk1.
  • Mab DC101 and paclitaxel combined enhanced apoptosis in the tumor and endothelial cells compared with other treatment (P < 0.005).
  • The antitumor effect was mediated by inhibition of angiogenesis and induction of both tumor cell and endothelial cell apoptosis.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Paclitaxel / therapeutic use. Receptor Protein-Tyrosine Kinases / immunology. Receptors, Growth Factor / immunology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis. Cell Division. Endothelial Growth Factors / genetics. Fibroblast Growth Factor 2 / genetics. Humans. Interleukin-8 / genetics. Lymphokines / genetics. Male. Matrix Metalloproteinase 9 / genetics. Mice. Mice, Nude. Microcirculation / pathology. Neovascularization, Pathologic / prevention & control. RNA, Messenger / analysis. Receptors, Vascular Endothelial Growth Factor. Transcription, Genetic. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10914704.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 67914; United States / NCI NIH HHS / CA / CA 67952
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / DC101 monoclonal antibody; 0 / Endothelial Growth Factors; 0 / Interleukin-8; 0 / Lymphokines; 0 / RNA, Messenger; 0 / Receptors, Growth Factor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 3.4.24.35 / Matrix Metalloproteinase 9; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia.
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


48. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • It is a case of both synchronous and metachronous primary malignant neoplasms occurring in four different organs.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • We also review the medical literature for the possible causes of multiple primary malignant neoplasms.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kersun LS, Wimmer RS, Hoot AC, Meadows AT: Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2004 Mar;42(3):289-91
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia.
  • [MeSH-major] Cyclophosphamide / adverse effects. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Urinary Bladder Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Child. Female. Hematuria. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Neoplasm Invasiveness / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Urinary Incontinence

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14752871.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down






Advertisement